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Dear Editor,
The off-label use of medication is an important part of medical
practice worldwide. Off-label medication use enables clini-
cians practicing to become more knowledgeable about treat-
ment alternatives. Off-label medication use may lead to inno-
vative new uses of old medications and new therapeutic
advances, particularly when approved treatments have failed.
Off-label use of medication can vary from being experimental
or innovative or controversial to standard practice and even
state-of-the-art treatment. So off-label use of medication
carries a higher risk for the patient and the practitioner than
its registered use. Awareness remains an issue in many con-
ditions for both patients and prescribers, but unfortunately,
abuse and overpromotion continue too frequently, so extra
care should be taken. For example, since more than 35 years,
the international medical scientific community tries to solve
the problem of the off-label use of pediatric drugs. But the
detailed analysis of the problem shows not only a still remain-
ing lack of medical knowledge, but also persistent weaknesses
in the ethical, legal, medical, pharmacological, and political
practices that surround the phenomenon of off label use in
pediatrics [1]. So off-label use has become a worldwide prob-
lem. The key to solving this problem is how to regulate off-
label promotion. Off-label prescribing is legal in the USA and
in many other countries. Zhang et al. reported in their study
that seven countries had laws related to off-label medication
use: American, Germany, Italy, Netherland, New Zealand,
India, and Japan. Except India [2], the rational off-label
medication use was allowed in the other six countries. The
right to prescribe off-label drug was defined in Britain and
Ireland. Ten countries published guidelines or statements re-
lated to off-label medication use by their official departments
and academic organizations [3]. According to FDA regula-
tions, physicians may prescribe drugs for off-label use, but
drug manufacturers may not promote such uses [4]. The off-
label prescriptions must better serve patient needs than alter-
natives and must be supported by evidence or experience to
demonstrate safety and efficacy in the UK. But the responsi-
bility for regulating and monitoring use of innovative off-label
medications rests at a local level. Medical institutions must
have an institutional policy to govern innovative off-label
medication use. The institutional policy may be more efficient
to focus on the medications that effective and risk, rather than
attempting to control the use of all medications prescribed
innovative off-label use. Ansani et al. had designed a strategy
to promote safe, innovative off-label use of medications that
was a formal, approved, systematic approach for structured
therapeutic guideline recommendations for innovative off-
label drug use. This approach includes crafting supporting
documents, grading the level of scientific evidence, and incor-
porating patient safety monitoring into medication review [5].
Off-label medication use is common practice in China. Our
study shows that the off-label drugs percentage in therapeutic
drugs during hospitalization was 47.64 %, most case lacked
evidence of clinical efficacy [6]. Compared with the USA,
China law does not currently specify whether off-label med-
ication use is illegal. Ministry of Health, Measures for the
Administration of Prescriptions Chapter 4, Section 14 pro-
vides that “In the description of the drug, physicians should be
based on medical, prevention, health care needs, according to
the diagnostic and treatment practices, and drug indications,
pharmacological effects, usage, dosage, contraindications, ad-
verse reactions and precautions in the package insert.” This
means that prescribing of approved drugs must be based on
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the diagnostic and treatment practices and/or on the package
insert. So there are no standardized regulations on off-label
use in China. Despite the widespread recognition of the prob-
lem, few institutions have a mechanism to control innovative
off-label medication use in China. Medical institutions must
take the responsibility for regulating and monitoring use of
innovative off-label medications. Therefore, a management
guideline for off-label medication use is urgently needed in
medical institution. Ideally, any off-label medication use
should be in the context of a study in which informed consent
is given and approval by an Institutional Review Board is
obtained. This article describes a strategy, a systematic ap-
proach to innovative off-label medication prescribing and
provides a mechanism for the evolution and promotion of
standards of medical care for this situation, ensure oversight
of patient safety, and prospectively assess efficacy.
We convened a multidisciplinary ad hoc task force (Institu-
tional Review Board) to actively address innovative off-label
medication use and to define optimal medication management
through the hospital’s Pharmacotherapy, which traditionally
have been responsible for promoting safe, effective medication
use and making recommendations for drug use through formu-
lary review. The committee should be considered the arbiter of
off-label use, should develop therapeutic guideline for innova-
tive off-label use of an approved drug. Tomaintain focus on the
underlying evidence, a grading management system was de-
veloped, which grade the quality of the evidence of off-label
medication use and to evaluate the strength of recommendation
of the intervention that is proposed in the information of off-
label medication use. The system looks at four factors to
determine the quality of the evidence: study design (the number
and size of clinical trials,), study quality (study design and
conduct), consistency, and directness (or generalizability). After
combining the four components and assessing the grade of the
evidence, the strength of recommendation of the intervention is
established. The practicing clinicians use them in making safe
and rational formulary decisions about patient care. Generally,
all available data and information would be collected, assessed,
and analyzed by applying a ranked grading system. The ele-
ments required by policy within this written proposal must
incorporate an executive summary, rationale, background, ev-
idence support, appropriate selection criteria for patients, in-
structions for clinical conduct (including dose, duration, and
regimen), clinical efficacy and safety outcomes, patient in-
formed consent, a proposed timeline for evaluation (with a
maximum limit of a year), and pharmacoeconomic outcomes.
Providing information should include approved labeling, com-
prehensive bibliography of publications related to off-label use
and other available information about risks of this use, plus
representative publications reaching conclusions regarding this
use including contrary or different statement. Further, the fol-
lowing principles should guide the innovative off-label use of
medications:
1. Patient safety should be the primary consideration.
2. Physicians may also need to self-monitor their prescribing
practices in order to avoid inappropriate.
3. Off-label prescribing should be meet ethical obligations to
the patient and society.
4. The ultimate responsibility for the safety and efficacy of
off-label use resides with the prescriber.
5. The hospital’s Pharmacotherapy Committee offers expe-
dited passport services to urgent patient care issues for off-
label prescribing.
The hospital’s Pharmacotherapy Committees has established
five categories in the standardized formulary review to indicate
the conditions under which information about the off-label uses
of drugs to adjudicate conflict between physicians, patient, and/
or pharmacy in the initial evaluation or subsequent interim
analysis of new information, by which based on the grading
management system to evaluate the methodological rigor of
clinical data. The categories are the following:
Category A The off-label medication use, in the same man-
ner as it would be for an on-label use grounded
by scientific evidence, is inconsistent with pres-
ent labeling, but that do the “Chinese National
Formulary,” medical textbooks, the latest clini-
cal practice guidelines, clinical pathways, and
other authoritative information on expert con-
sensus support. In this case, it is consistent with
the policy ofMeasures for the Administration of
Prescriptions that the physicians prescribe ther-
apies according to “the diagnostic and treatment
practices.” The formulary review is similar to
process of approved medication use. For exam-
ple, propranolol can be used migraine headache
treatment in “Chinese National Formulary,”
which is unapproved in present labeling [7].
There are no restrictions in the situation.We call
this conversation routine therapeutic consent.
Category B The off-label medication use may originate from
a presumed drug class effect. This approval
grants formulary addition and is based on the
judgment that adequate evidence exists for an
off-label formulary addition. It requires more
discussion than routine therapeutic consent but
less formality than written informed consent.
There is requirement of double signatory by
the physician on the prescription in the formu-
lary review. We call this type of consent aug-
mented therapeutic consent. For example, the
use of propranolol for portal hypertension could
reduce portal pressure that the pharmacological
effect is an extension of splanchnic vasocon-
striction of propranolol.
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Category C The off-label use medication has a reasonable
therapeutic rationale but here is insufficient ev-
idence to thoroughly allay concerns about its
safety, efficacy, and cost-effectiveness for the
innovative use, yet it is not considered a clinical
research. This category restricts drug use within
a “therapeutic guideline for innovative off label
use of an approved drug,” and require rigorous
informed consent for the situation whereby pa-
tients are informed of potential risks and bene-
fits and understand that the clinical outcome of
this medication use is uncertain prior to admin-
istering the drug. Upon review by the Board, the
Committee must again review for a final vote of
formulary status. For example, the therapeutic
guideline of propranolol for infantile hemangi-
oma must be approved to formulary by the
hospital’s Pharmacotherapy Committee. We
call this therapeutic guideline approved thera-
peutic consent.
Category D The off-label use medication has little or no
supporting evidence. The evidence provides
information only about cases. The off-label
use (with very low certainty of net benefit) for
the indication is restricted to clinical research
(is considered experimental). Evidence of po-
tential harms of the off-label use should be
sought out and considered at least as inclusively
and rigorously as the evidence for potential
benefit. The off-label use generally should be
limited to the context of research protocols.
Patients should engage in a formal informed
consent process with the physician researcher
before receiving drugs for experimental off-
label use. Patients must understand that the
purpose of experimental off-label use is to gen-
erate data to improve medical care for future
patients rather than to provide medically indi-
cated treatment, although the patient may ben-
efit. An application for off-label use medication
should be submitted and approved by the hos-
pital’s Pharmacotherapy Committee and hospi-
tal’s Ethics Committee. We call this therapeutic
approach specified therapeutic consent. For ex-
ample, the application of propranolol to treat
anxiety disorders must be submitted and
approved.
Category X There is evidence that benefit of the off-label
use medication is unfavorable, and the risks
involved in off-label use of the medication in
the indication clearly outweigh potential bene-
fits. The proposed clinical use of a medication is
considered inappropriate, and the medication
use in the requested manner is not permitted
by the hospital’s Pharmacotherapy Committee.
More and more people recognized that public health might
be advanced if health-care professionals were to receive in-
formation about the off-label use that is truthful and not
misleading. But busy physicians would not have the time to
do their own due diligence regarding off label uses; therefore,
there is a need for informing physicians about the evidence
supporting off-label prescriptions. Before considering off-
label use, supporting safety and efficacy evidence must be
carefully evaluated and a risk–benefit determination made,
especially when alternatives with approved labeling are avail-
able for the intended off-label use. Our strategy that involves
review of all off-label uses of medications by formulary
review and input from expert panels develops a comprehen-
sive and workable ethical framework that prioritizes scrutiny
of off label prescribing for practicing physicians. This ad-
dresses issues related to off-label prescribing at a specific
institutional level. By classifying off-label uses as five cate-
gories, this practical strategy grounds recommendations for
prescribing practices in a judgment of the strength of the
evidence for net health benefit. This modifies innovative off-
label medication use decisions as well as contributes to
expanding clinical information bases. Such restraint not only
protects patients from unsafe or ineffective off-label uses but
also guards physicians against tort liability and medical mal-
practice suits.
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